This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Levocarnitine propionate is a medication indicated in the treatment of peripheral arterial disease and to increase exercise tolerance in congestive heart disease.
- Generic Name
- Levocarnitine propionate
- DrugBank Accession Number
- DB15980
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Levocarnitine propionate (DB15980)
- Weight
- Average: 217.265
Monoisotopic: 217.131408096 - Chemical Formula
- C10H19NO4
- Synonyms
- L-Carnitine propionate
- Propionyl-L-carnitine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Levocarnitine propionate hydrochloride 12FW2YBF04 119793-66-7 Not applicable
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0HU2UI27HF
- CAS number
- 20064-19-1
- InChI Key
- UFAHZIUFPNSHSL-MRVPVSSYSA-N
- InChI
- InChI=1S/C10H19NO4/c1-5-10(14)15-8(6-9(12)13)7-11(2,3)4/h8H,5-7H2,1-4H3/t8-/m1/s1
- IUPAC Name
- (3R)-3-(propanoyloxy)-4-(trimethylazaniumyl)butanoate
- SMILES
- CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C
References
- General References
- AIFA: Dromos (Levocarnitine Propionate) Intravenous Injection [Link]
- External Links
- Human Metabolome Database
- HMDB0062514
- ChemSpider
- 164090
- ChEBI
- 53210
- ChEMBL
- CHEMBL3392074
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Intermittent Claudication / Peripheral Vascular Disease Patient 1 3 Completed Treatment Peripheral Arterial Disease (PAD) 1 3 Terminated Treatment Ulcerative Colitis 2 2 Completed Treatment Ulcerative Colitis 1 2 Recruiting Treatment Heart Failure With Preserved Ejection Fraction (HFpEF) 1 1 Completed Treatment Peripheral Arterial Disease (PAD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Parenteral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.152 mg/mL ALOGPS logP -2.3 ALOGPS logP -3.7 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 4.19 Chemaxon pKa (Strongest Basic) -7.1 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 66.43 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 77.26 m3·mol-1 Chemaxon Polarizability 22.63 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 07, 2020 14:07 / Updated at May 07, 2021 21:09